Thanks to ROS1ders’ Partner Turning Point Therapeutics


Dear Turning Point Therapeutics, Thank you so much for inviting me to speak to your employees about my personal ROS1 lung cancer story and the work of The ROS1ders. I truly appreciate your willingness to consider a patient perspective on ways to improve awareness of and access to biomarker testing and clinical trials for cancer patients. … Continue reading Thanks to ROS1ders’ Partner Turning Point Therapeutics

Ros1derings : August Edition


The second issue of our newsletter was released just over two weeks ago. For those who have missed it, you can grab it here : Ros1derings : August edition Contents include: A feature about Luna Okada, a 6.5 year ROS1der Some numbers about Xalkori use Fundraising updates Tips for traveling with stage 4 cancer An … Continue reading Ros1derings : August Edition

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC


Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada. This submission was led by … Continue reading pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Announcing The ROS1ders newsletter “ROS1derings”


We’ve created a newsletter! This newsletter will become a quarterly communication tool for The ROS1ders. In this issue, Marisa Wittebort shares tips for contributing to the ROS1 tissue study, Bärbel Söhlke​ writes about ROS1 activities in Europe, Jeff Wynne details what his data base shows about ROS1 members, and Lisa Goldman offers a fundraising update. … Continue reading Announcing The ROS1ders newsletter “ROS1derings”

The ‘Ross-Wonders’, Cancer’s New Superheroes


You’ve likely never heard the story of how three young women, who call themselves “ROS1ders” from a rare form of lung cancer they share, may be turning the nation’s 46-year-old war on cancer on its head. The women were diagnosed with a gene mutation called a ROS1 fusion. Read more here

ROS1ders Meet the Rodents


What happens when you tell someone they have a terminal diagnosis and potentially less than a year to live? They cry, get scared, worry about the loved ones they will leave behind, and grieve. And if they are anything like the ROS1ders, they organize and make stuff happen. It has not been easy, and along … Continue reading ROS1ders Meet the Rodents